RenovoRx (RNXT) Fundamental Analysis: Revenue, Earnings & Valuation

1.77 / 10

Underperform

Fundamental metrics score 1.77/10, rated Underperform. While current‑liabilities ratio and interest coverage appear decent, asset‑MV and revenue‑MV are negative, dragging the rating down. Overall, the company’s financial health is concerning, limiting its investment appeal.

Analysis Checks(8/10)

Revenue-MV

Value-3.69

Score1/3

Weight29.39%

1M Return4.09%

Total operating revenue (YoY growth rate %)

Value78.03

Score2/3

Weight0.81%

1M Return0.13%

Inventory turnover ratio

Value2.20

Score2/3

Weight-6.75%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value60.23

Score2/3

Weight2.29%

1M Return0.36%

PB-ROE

Value3.08

Score2/3

Weight55.20%

1M Return7.29%

Long-term debt to working capital ratio (%)

Value0.14

Score3/3

Weight5.18%

1M Return0.87%

Interest coverage ratio (EBIT / Interest expense) (%)

Value15.64

Score2/3

Weight-6.86%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value92.19

Score2/3

Weight0.33%

1M Return0.05%

Cost of sales ratio (%)

Value33.79

Score2/3

Weight-6.48%

1M Return-1.13%

Asset-MV

Value-0.49

Score0/3

Weight26.90%

1M Return4.00%

Is RNXT fundamentally strong?

RNXT scores 1.77/10 on fundamentals and holds a Premium valuation at present. Backed by its -225.62% ROE, -994.48% net margin, -4.01 P/E ratio, 8.27 P/B ratio, and 20.00% earnings growth, these metrics solidify its Underperform investment rating.